Myelodysplastic Syndromes (MDS)

Summary Bone marrow failure syndromes (BMFS) are a diverse group of disorders that commonly present with pancytopenia and require a structured approach to evaluation. Initial assessment focuses on excluding reversible causes, followed by consideration of inherited and acquired…

Key Points Infection risk in MDS is dynamic and biologically driven, influenced by neutropenia, therapy and immune reserve Treatment with azacitidine increases infection risk, with most infections occurring in the first six cycles Infection is a major cause of morbidity and…

Abstract Purpose Neutropenic diet (ND) has historically been recommended to reduce infectious complications in patients with cancer. Although its use has declined over the past decade, recent studies, particularly in patients undergoing hematopoietic stem-cell transplantation…

Abstract Post-transplant cyclophosphamide (PTCy) has transformed graft-versus-host disease (GVHD) prophylaxis but its role in matched-donor reduced-intensity allogeneic hematopoietic cell transplantation (allo-HCT) remains uncertain. We retrospectively analyzed adults with AML or…

Valeria Santini, MD, discusses advances in the treatment of myelodysplastic syndromes, including new therapeutic options for patients with lower-risk disease. “We do not only want to improve the quality of life, but also prolong survival,” Dr. Santini said. In addition to…

Abstract Inflammation accelerates evolutionary dynamics of hematopoietic stem cells (HSCs) in clonal hematopoiesis and myeloid neoplasms. We studied HSCs, progenitors and immune cells from patients with myeloproliferative neoplasms at baseline and following interferon-α (IFNα)…

Patients with erythropoiesis-stimulating agent (ESA)-refractory lower-risk myelodysplastic syndrome (LR-MDS) continued to benefit from the first-in-class allosteric NEK7/NLRP3 inhibitor ofirnoflast, according to results from a phase 2 study. With its favorable safety profile…